New drug application
Tepezza Powder for Concentrate for Solution for Infusion 500mg/vial
11 September 2026
The summary report for this therapeutic product is available for download
Summary report for Tepezza
Active ingredient | Product Registrant | Approval date | Summary report |
|---|---|---|---|
Teprotumumab | Amgen Biotechnology Singapore Pte Ltd | 15 May 2026 |
